Sofosbuvir, Velpatasvir and Voxilaprevir

Therapeutic indications

Sofosbuvir, Velpatasvir and Voxilaprevir is indicated for:

Hepatitis C

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Sofosbuvir/velpatasvir/voxilaprevir combination is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older and weighing at least 30 kg.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Sofosbuvir, Velpatasvir and Voxilaprevir is contraindicated in the following cases:

Lactation

Lactation

Dabigatran etexilate, rosuvastatin

at least one of
Dabigatran
Rosuvastatin

Ethinylestradiol

17 alpha-Ethinylestradiol

Strong inducers of P-gp, CYP2B6, CYP2C8, CYP3A4

at least one of
Carbamazepine
Phenobarbital
Phenytoin
Rifampicin
Rifabutin
Hypericum perforatum (St John's Wort)
Strong potency CYP3A4 inducers

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2023: VOSEVI Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈